Hypothesis

The prevailing view attributes cognitive aging to accumulated damage—Aβ/pTau aggregates, neuroinflammation, synaptic loss, and telomere shortening Klotho deficiency accelerates neuronal telomere attrition and stress vulnerability. But there's another way to think about it. The "archive hypothesis" suggests that cognitive decline might instead reflect the computational cost of maintaining an exponentially growing associative memory on fixed neural hardware. A 70-year-old brain isn't broken—it's running search queries across seven decades of indexed experience on neurons that haven't scaled.

This leads to a specific prediction: if aged neurons are computationally saturated rather than primarily damaged, then AAV-mediated longevity gene therapy (hTERT, Klotho) might work not by "repairing" pathology but by expanding the computational bandwidth available for memory indexing and retrieval. The reversibility of dementia pathology with AAV-hTERT/Klotho AAV-hTERT/Klotho therapy reverses dementia pathology by elongating telomeres and improving cognition could reflect restored capacity to manage archival load, not merely cellular repair.

Mechanistic Framework

I think age-related transcriptional changes in neurons represent a resource allocation shift rather than pure damage. As associative networks expand, neurons increasingly divert transcriptional resources toward maintaining synaptic plasticity machinery necessary for memory integration, at the expense of housekeeping and stress resilience pathways. This creates a vulnerability window—not irreversible damage—where external supplementation of longevity genes tips the balance back toward computational capacity.

Prediction: AAV-delivered longevity genes should preferentially enhance expression of activity-dependent immediate-early genes (c-Fos, Arc, Egr1) in aged neurons during memory encoding tasks, rather than uniformly reversing pathological markers. The therapeutic effect should correlate with computational throughput (measured via neural dynamics during complex memory retrieval) rather than with traditional pathological benchmarks.

Testable Predictions

1. Computational load manipulation: In aged mice performing associative memory tasks of increasing complexity, AAV-Klotho treatment should show dose-dependent enhancement specifically for high-load conditions, with minimal effect on simple recall.

2. Temporal expression dynamics: If the mechanism is bandwidth expansion rather than damage repair, transgene expression should acutely enhance neuronal responsiveness within days recent advances using engineered capsids developed via directed evolution for superior CNS targeting, not weeks as would be expected for aggregate clearance or cellular remodeling.

3. Synaptic scaling without protection: Aged neurons transduced with longevity genes should show increased synaptic density primarily in association cortex (high memory load regions) rather than primary sensory cortex, consistent with differential computational demand.

Falsifiability

This hypothesis is falsified if: (a) AAV longevity therapy shows equivalent cognitive rescue in young animals subjected to artificial pathology (via acute toxin models) versus naturally aged animals, suggesting generic neuroprotection; (b) histopathological improvements (Aβ clearance, inflammation reduction) fully account for cognitive rescue without computational measure correlations; or (c) cognitive enhancement in aged animals shows no relationship to task complexity—indicating general neuronal health restoration rather than bandwidth-specific effects.

Implications

If validated, this framework reframes AAV longevity therapy from damage repair to computational augmentation—effectively giving aging neurons more "RAM" to manage their archival burden. This would redirect therapeutic development toward optimizing gene delivery for specific circuits involved in associative memory, rather than pursuing universal neuroprotection strategies.